HERCULES, Calif. - Bio-Rad Laboratories (NYSE:BIO), Inc. (NYSE: BIO and BIO.B), a $8.49 billion market cap company known for its life science research and clinical diagnostics products, has announced ...

Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin ...

In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...

Bio-Rad Labs (BIO) has delivered a -7.92% change over the past year, with a 52-week range between 211.43 and 373.69. What Is the Average Daily Trading Volume of Bio-Rad Labs (BIO)? The average daily ...

Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...

Normal Schwartz has been the Chief Executive Officer or CEO, President, and Chairman of Bio-Rad laboratories since 2003. Meet Bio-Rad laboratories chief executive officer or CEO, Norman Schwartz. The ...

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...

It's been a good week for Bio-Rad Laboratories, Inc. (NYSE:BIO) shareholders, because the company has just released its latest quarterly results, and the shares gained 7.7% to US$285. The results were ...

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...

Oct 26 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro ...

Testifying in a retaliation trial pitting a fired attorney against his former employer Bio-Rad Laboratories, the company’s CFO said Tuesday the attorney’s erratic behavior included an incident that ...